Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A prospective economic evaluation of basiliximab (Simulect (R)) therapy following renal transplantation
Autore:
Lorber, MI; Fastenau, J; Wilson, D; DiCesare, J; Hall, ML;
Indirizzi:
Yale Univ, Sch Med, Dept Surg, Sect Organ Transplantat & Immunol, New Haven, CT 06520 USA Yale Univ New Haven CT USA 06520 antat & Immunol, New Haven, CT 06520 USA
Titolo Testata:
CLINICAL TRANSPLANTATION
fascicolo: 5, volume: 14, anno: 2000,
pagine: 479 - 485
SICI:
0902-0063(200010)14:5<479:APEEOB>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALLOGRAFT RECIPIENTS; COST-EFFECTIVENESS; INDUCTION THERAPY; CHRONIC REJECTION; SURVIVAL;
Keywords:
economic analysis; immunosuppression; renal transplantation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Lorber, MI Yale Univ, Sch Med, Dept Surg, Sect Organ Transplantat & Immunol, POB 208062,333 Cedar St,FMB 112, New Haven, CT 06520 USA Yale Univ POB 208062,333 Cedar St,FMB 112 New Haven CT USA 06520
Citazione:
M.I. Lorber et al., "A prospective economic evaluation of basiliximab (Simulect (R)) therapy following renal transplantation", CLIN TRANSP, 14(5), 2000, pp. 479-485

Abstract

Background: Immunoprophylaxis with basiliximab (Simulect(R)), an anti-interleukin-2-receptor (anti-IL-2R; CD25) chimeric monoclonal antibody, has been demonstrated to significantly reduce the incidence of acute cellular rejection in adult renal allograft recipients (32% vs. placebo, p < 0.01). Methods: An economic evaluation was conducted as part of a U.S. multi-center, randomized, double-blind, placebo-controlled clinical trial comparing basiliximab plus dual immunosuppressive therapy (cyclosporine modified [Neoral(R)] and corticosteroids) to dual therapy alone. Healthcare resources utilized by the 346 subjects in the 'intent-to-treat' population were prospectively collected over the 1-yr study period. Direct medical costs were determined font all hospitalizations, outpatient provider visits, procedures (excluding the initial transplant procedure), laboratory and diagnostic tests,and immunosuppressants, including basiliximab when administered. Results: Total first-year medical costs were lower for the basiliximab group than for the placebo group ($28 927 vs. $32 300, difference = $3373), although this difference was not statistically significant. First-year hospital casts for treating acute rejection were also lower for the basiliximab group ($9328 vs. $10 761, difference = $1433); however, this difference did not achieve statistical significance. Importantly, the efficacy analysis demonstrated a significant reduction in the incidence of acute rejection (38 vs. 55%, p < 0.01) in the basiliximab arm, and this was accomplished without increasing the overall cost of care. Fewer basiliximab-treated patients (8 vs. 15%, p = 0.03) were hospitalized. This observation suggested less serious illness and reduced treatment costs among basiliximab-treated patients, because the overall incidence of infection was similar between the groups. The adverse event profile of patients receiving basiliximab was clinically and economically indistinguishable from that of those treated with placebo. Conclusion: Induction immunosuppression with basiliximab, combined with cyclosporine modified and corticosteroids, was therapeutically beneficial andcontained medical costs during the initial post-transplant year.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 09:21:53